Income From Continuing Operations - S2Medical AB (publ) (STO:S2M) - Alpha Spread
S

S2Medical AB (publ)
STO:S2M

Watchlist Manager
S2Medical AB (publ)
STO:S2M
Watchlist
Price: 0.024 SEK Market Closed
Market Cap: 6.4m SEK
Have any thoughts about
S2Medical AB (publ)?
Write Note

S2Medical AB (publ)
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

S2Medical AB (publ)
Income from Continuing Operations Peer Comparison

Comparables:
O
OSSD
XVIVO
D
DOXA
BACTI B
V
VIMIAN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
S2Medical AB (publ)
STO:S2M
Income from Continuing Operations
-kr1.9m
CAGR 3-Years
54%
CAGR 5-Years
34%
CAGR 10-Years
N/A
O
OssDsign AB
STO:OSSD
Income from Continuing Operations
-kr130.5m
CAGR 3-Years
-16%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Xvivo Perfusion AB
STO:XVIVO
Income from Continuing Operations
kr120.7m
CAGR 3-Years
N/A
CAGR 5-Years
77%
CAGR 10-Years
34%
D
Doxa AB
STO:DOXA
Income from Continuing Operations
-kr208.2m
CAGR 3-Years
-145%
CAGR 5-Years
N/A
CAGR 10-Years
-25%
Bactiguard Holding AB
STO:BACTI B
Income from Continuing Operations
-kr138.4m
CAGR 3-Years
-53%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
V
Vimian Group AB
STO:VIMIAN
Income from Continuing Operations
€10.5m
CAGR 3-Years
-44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is S2Medical AB (publ)'s Income from Continuing Operations?
Income from Continuing Operations
-1.9m SEK

Based on the financial report for Jun 30, 2024, S2Medical AB (publ)'s Income from Continuing Operations amounts to -1.9m SEK.

What is S2Medical AB (publ)'s Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
34%

Over the last year, the Income from Continuing Operations growth was 93%. The average annual Income from Continuing Operations growth rates for S2Medical AB (publ) have been 54% over the past three years , 34% over the past five years .

Back to Top